Press Room

DDL 2021

Start
Wednesday, December 08, 2021 - 00:00
End
Friday, December 10, 2021 - 00:00
Location: Online

 

Schedule a meeting today

and connect with one of our Inhalation Experts

 

Hovione's Scientists On-Demand Presentations:

 

Hovione scientist at DDL Conference Nasal PAMPA intranasal drug permeability | Hovione

 

Nasal-PAMPA: a novel in vitro tool for prediction of intranasal drug permeability

Presenter: Patrícia Henriques, PhD Student, R&D DPD 

 

Abstract:

In nasal drug product development, biorelevant in vitro methodologies are vital in order to select promising compounds or formulations, potentially reducing pre-clinical and clinical trials. Permeability assays are often applied to predict drug absorption and bioavailability. For nasal delivery products, permeation models include ex vivo models using excised nasal mucosa and in vitro cell culture models. However, ex vivo models present high variability and cell culture models are very time consuming. The Parallel Artificial Membrane Permeability Assay (PAMPA) has emerged as a high throughput screening tool to evaluate drug permeability, and it has been applied to several barriers such as the intestine, skin or blood-brain-barrier. Herein, a new PAMPA model was developed and optimized to predict nasal permeability, using a biorelevant donor medium containing mucin. The apparent permeability (Papp) of 15 reference compounds was assessed in six different experimental conditions. The model with 0.5% (w/v) mucin in the donor compartment and 2% (w/v) phosphatidylcholine in the lipid membrane correctly distinguished high and low permeable compounds, with no false positives or negatives. In addition, it exhibited the highest correlation with permeation across human nasal epithelial RPMI 2650 cells (R2 = 0.71). Overall, the optimized PAMPA model was reproducible, predictive and inexpensive, showing to be a promising non-cell based and biorelevant in vitro tool that could be applied in an early screening stages of new nasal drug delivery products.

Hovione scientist at DDL Conference DPI formulation screening: particle-particle interaction | Hovione
Hovione scientist Joao Pereira at DDL Conference DPI formulation screening: particle-particle interaction | Hovione

 

Leveraging DPI formulation screening: particle-particle interaction

Presenters:

Raquel Borda D’Água, Associate Analytical Scientist, R&D Analytical Development

João Pereira, Manager R&D Analytical Development

 

Abstract:

Dry powder inhalers (DPIs) have attracted enormous attention worldwide due to its local targeting, rapid drug effect and reduced systemic toxicity. However, DPI formulations consist of highly cohesive powders that tend to agglomerate. Therefore, understanding the role of cohesive-adhesive forces in different formulations and establishing a predictive approach for aerodynamic particle size distribution (aPSD) is thus, highly beneficial. The purpose of this study is to explore the relationship between powder dispersibility with the aerodynamic performance of different DPI formulations. Sympatec was used to characterise powder dispersibility and inherent cohesion and adhesion forces at different pressures. Powder dispersibility obtained by Sympatec and aerodynamic properties from the NGI analysis were evaluated in order to deeper understand the characteristic behaviour of these formulations

 

 





 

Take advantage of cutting-edge particle engineering technologies highly skilled responsive staff and state of the art analytical facilities.

 

 

Everything for Inhalation

Inhalation high performance APIs particle engineering formulation DPIs pdf | Hovione

 





 



 

Learn more about DDL2021

 

 



 





 

Also in the Press Room

See All

In an interview with Executiva, a portuguese media outlet focused on women´s leadership, Diane Villax, co-founder and long-standing leader of Hovione, reflects on her journey and the company’s development over more than six decades. Diane Villax’s career began at a time when few women worked outside the home. At 19, she joined a trading company as a foreign languages correspondent, where she developed essential business skills — including commercial correspondence, banking and export procedures — that later proved instrumental in helping her husband, Ivan Villax, establish Hovione in 1959. From its earliest days operating in the family home in Lisbon, Hovione adopted an international outlook. The company’s first major customers were in Japan, setting demanding quality standards that helped shape its long-term position in global markets. Over the following decades, Hovione expanded its footprint with the construction of its first manufacturing site in Loures (1969), followed by expansion to Macau (1986), the United States (New Jersey, early 2000s) and Ireland (Cork). The company grew into a global organization with more than 2,500 employees — including over 300 scientists — and a reputation as a preferred supplier to leading pharmaceutical companies worldwide. Throughout the interview, Diane highlights the values that have guided the company’s development: a commitment to excellence, a strong work ethic, and a focus on quality and long-term relationships. Although she did not have formal business training, she learned “on the job” and brought discipline, precision and structure to her role — particularly in the company’s early financial and administrative leadership. Now in her nineties and an active member of Hovione’s Board of Directors, Diane Villax remains engaged with the company’s evolution and governance, reflecting a continued commitment to its long-term development. Her story reflects entrepreneurial drive, resilience and long-term leadership — and offers insight into the values that have shaped Hovione’s trajectory for more than six decades. Read the full interview at Executiva.pt (in portuguese).    

Article

Hovione’s Diane Villax: “I was not brought up to be a business woman”

Feb 23, 2026